KRRO Korro Bio
- 49.700
- +0.700+1.43%
Korro Bio News
BMO Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Korro Bio(KRRO.US), With a Forecast Between $100 to $180
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Gilead Sciences (GILD)
Korro Bio Analyst Ratings
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $180
RBC Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $95
Analysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)
Buy Rating on Korro Bio Amid Strong KRRO-110 Preclinical Results and Upcoming Clinical Milestones
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $100
Buy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic Profile
Korro Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Korro Bio Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for Korro Bio (KRRO)
Korro Bio Earns Buy Rating From Analyst Mitchell Kapoor on Groundbreaking RNA Editing Technology and Strong Preclinical Results
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
Korro Bio Earns Buy Rating on Promising RNA Editing Technology for AATD Treatment
Korro Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Shockwave Medical (SWAV) and Korro Bio (KRRO)
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Veeva Systems (VEEV)
Analysis
Price Target
No Data
